Neoadjuvant androgen ablation therapy prior to radical prostatectomy - Quantum leap or hope unrealized?

Current Opinion in Urology

Volumn 6, Issue 5, 1996, Pages 254-257

  Trachtenberg, John ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0029800572     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199609000-00005     Document Type: Short Survey

References (19)

1. Partin AW, Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 1994, 152:1358-1368.
2. Brendler CB: The role of radical prostatectomy In the treatment of prostate cancer. CA Cancer J Clin 1992, 42:212-216.
3. Ackerman DA, Barry JM, Wicklund RA. Olson N, Lowe BA: An analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993, 150:1845-1852.
4. Fair WR, Aprikian AG, Cohen D, Sogani P, Reuter V: Use of neoadjuvant therapy in clinically localized prostate cancer. Clin Invest Med 1993, 16:516-519.
5. Epstein JI, Carmichael M, Partin AW, Walsh PC: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J Urol 1993, 149:1478-1484.
6. Lemer S, Blute M, Bergstralh, Bostwick D, Eickholt J, Zincke H: Analysis of risk factors with pathologically confined prostate cancer after radical retropubic prostatectomy. J Urol 1996, 156:137-143.
7. Epstein JI, Pizov G, Walsh PC: Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 1993, 71:3582-3593.
8. Smith RC, Brendler CB, Partin AW: Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis In men with clinically localized prostate cancer [Abstract]. J Urol 1995, 153:128.
9. Monfette G, Dupont A, Labrie F, Boivin JC, Tetu B: Multiple advantages of prior and post radical prostatectomy with combined endocrine therapy [Abstract]. Eur Urol 1990, 18 (suppl 1):97.
10. Scott WW, and Boyd HL: Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of carcinoma of the prostate: a retrospective study based on 25 years of experience. J Urol 1969, 101:86-90.
11. Solomon MH, McHugh TA, Dorr RP, Lee F, Siders DB: Hormone ablation therapy as neoadjuvant therapy to radical prostatectomy. Clin Invest Med 1993, 16:532-535.
12. Narayan P, Lowe BA, Carrol PR, Thompson IM: Neoadjuvant hormone therapy and radical prostatectomy for clinical stage C carcinoma of the prostate. Br J Urol 1994, 73:544-548.
13. Fair WR, Aprikian A, Sogani P, Reuter V, Whitemore WF: The role of neoadjuvant hormone therapy in localized prostate cancer [Abstract]. Cancer 1993, 71(suppl):1031.
14. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieras M, Suburu R, Fradet Y, Lemay M, Tetu B, et al.: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993, 16:499-507.
15. Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood D, Paras Beaz A • • and The Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995, 154:424-428. This article provides a careful pathological analysis of the outcome of patients with T2bNxM0 treated with neoadjuvant androgen deprivation therapy.
16. Klotz LH, Goldenberg LS, Bullock MJ, Laplante S, and the Canadian • Uro-Oncology Group: Neoadjuvant Cyproterone acetate (CPA) therapy prior to radical prostatectomy reduces tumour burden and margin positivity without altering 6 and 12 month post treatment PSA: results of a randomized trial [Abstract]. J Urol 1996, 155:399. This abstract is one of two (see 18°) that questions the clinical effectiveness of neoadjuvant therapy because of not noting any difference in the two treatment groups in the important clinical parameter, PSA detection, after radical prostatectomy.
17. Poppel HV, Ridder D, Elgamal A, Van deVoorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, Baert L, and the Belgian Uro-Oncological Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer Interim results of a prospective randomized trial. J Urol 1995, 154:429-434.
18. Soloway M, Sharifi R, Wajsman Z, McLeod D, Wood D, Paras Beaz A • and The Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study-radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - initial results [Abstract]. J Urol 1996, 155:555. This abstract is one of two (see 16°) that questions the clinical effectiveness of neoadjuvant therapy because of not noting any difference in the two treatment groups in the important clinical parameter, PSA detection, after radical prostatectomy.
19. Zheng W, Bazinet M, Begin L, Aprikian A, Karakiewicz P, Elhilali M: • Histological changes induced by neoadjuvant androgen ablation therapy may result In the under detection of positive surgical margins and capsular penetration by prostate cancer [Abstract] J Urol 1996, 155:554. This important abstract suggests that more careful staining of the excised specimen of patients treated with neoadjuvant therapy can detect tumour at the margin when not apparent by conventional means.